The micrograph shows abundant (malignant) plasma cells with the occasional Mott cell. Credit: Nephron.

Seattle Genetics has dosed the first patient in a Phase I clinical trial to examine the safety and tolerability of SEA-BCMA to treat patients with relapsed or refractory multiple myeloma (MM).

The open-label, multi-centre trial is expected to enrol around 65 patients in the US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Seattle Genetics plans to carry out a dose escalation phase followed by an expansion period.

In the dose escalation cohort, the trial is expected to assess the safety and tolerability of SEA-BCMA, as well as determine the maximum tolerated dose.

The expansion stage is designed to collect further data regarding safety and antitumour activity.

Primary endpoints of the trial are treatment-emergent adverse events (TEAEs), grade three or higher adverse events (AEs), serious adverse event (SAE), and others.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“SEA-BCMA represents a novel empowered antibody treatment approach that has demonstrated antitumour activity and an acceptable safety profile.”

Secondary endpoints include pharmacokinetic (PK) outcome, incidence of SEA-BCMA antitherapeutic antibodies (ATA) and overall survival (OS).

Seattle Genetics chief medical officer Roger Dansey said: “Despite recent advances in the treatment of multiple myeloma, it remains an incurable disease with a need for active and well-tolerated agents.

“BCMA is a validated therapeutic target for multiple myeloma.

“SEA-BCMA represents a novel empowered antibody treatment approach that has demonstrated antitumour activity and an acceptable safety profile in preclinical evaluation to date.”

SEA-BCMA is an experimental antibody developed using Seattle Genetics’ sugar engineered antibody (SEA) technology that aims to improve antibody-dependent cellular cytotoxicity.

MM is an aggressive form of cancer that develops in plasma cells. It is estimated to be the second most common blood cancer in the US.